抗てんかん薬の世界市場：現状分析と予測（2021年～2027年）

世界の抗てんかん薬の市場規模は、予測期間（2021年～2027年）中に約2％のCAGRで成長すると予測されています。

中枢神経系疾患の有病率の上昇、先天性異常や遺伝的疾患とそれに伴う脳奇形の発生率の上昇が、てんかんの効率的な診断と治療の需要を牽引し、抗てんかん薬市場の成長を促進すると考えられています。

当レポートでは、世界の抗てんかん薬市場について調査しており、市場の洞察、市場動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 制限
• ステークホルダー
• レポートで使用される通貨

第2章 調査方法または仮定

• 抗てんかん薬市場の調査プロセス
• 抗てんかん薬市場の調査手法
• 予測方法
• 回答者プロファイル
• 抗てんかん薬市場調査の主な目的

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 世界の抗てんかん薬市場へのCOVID-19の影響

第6章 世界の抗てんかん薬市場収益（2019年～2027年）

第7章 市場の洞察：薬剤クラス別

• 第一世代
• 第二世代
• 第三世代

第8章 市場の洞察：流通チャネル別

• 小売薬局
• 病院薬局
• オンライン

第9章 市場の洞察：地域別

• 北米の抗てんかん薬市場
  • 米国
  • カナダ
  • その他の北米
• 欧州の抗てんかん薬市場
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋地域の抗てんかん薬市場
  • 中国
  • 日本
  • インド
  • オーストラリア
  • その他のアジア太平洋地域
• その他

第10章 抗てんかん薬市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第11章 抗てんかん薬市場機会

第12章 抗てんかん薬市場動向

第13章 法律および規制の枠組み

第14章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第15章 バリューチェーン分析

第16章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第17章 企業概要

• Novartis AG
• GlaxoSmithKline Plc
• Johnson & Johnson Service Inc
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Zogenix
• Dr. Reddy's Laboratories Ltd.
• Alkem Labs
• SK Biopharmaceuticals
• Eisai Co.

第18章 免責事項

Global Antiepileptic Drug Market is anticipated to grow with an elevated CAGR of around 2% over the forecast period (2021-2027). Antiepileptic drugs are the category of drugs developed for the treatment of asymptomatic and idiopathic symptoms of epilepsy and seizures.

As per WHO, epilepsy accounts for a significant proportion of the world's disease burden, affecting around 50 million people worldwide. The estimated proportion of the general population with active epilepsy (i.e. continuing seizures or with the need for treatment) at a given time is between 4 and 10 per 1000 people. Thus, the rising prevalence of central nervous system disorders coupled with the rising incidence of congenital abnormalities or genetic conditions with associated brain malformations; are expected to drive the demand for efficient diagnosis and treatment of epilepsy. Thus, supporting antiepileptic drug market growth. Furthermore, the new drug approval and the collaborations of the government and private organizations are further expected to contribute significantly to the antiepileptic drug market's growth.

Some of the major players operating in the market are Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Zogenix, and Dr. Reddy's Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, and Eisai Co., among others. Several M&As along with partnerships have been undertaken by these players to develop new and advanced antiepileptic drugs.

Insights Presented in the Report

"Amongst Drug Class, Third generation segment expected to hold a major share during the forecast period."

Based on drug class, the market is classified into first generation, second generation, and the third generation. The second-generation segment accounted for a significant market share in 2020. The presence of the different classes of the drugs with the improved efficacy and specificity was responsible for significant market share in that year. However, during the forecast period, the third-generation drug class is predicted to have the fastest growth in the anti-epileptic drug market this is mainly due to the increased global focus on the new drug development and frequent drug launches of the category. For instance, In 2021, Alkem laboratories launched an antiepileptic drug named Brivasure that suppresses abnormal electrical activity in the brain.

"Amongst distribution channels, online pharmacies segment holds the major share"

Based on distribution channels, the market is divided into retail pharmacies, hospital pharmacies, and online pharmacies. The online pharmacies category is anticipated to grow at a rapid rate in the upcoming years. This is due to the rising prevalence of internet penetration and growing government focus and investments in new-age start-ups in the digital space, especially in developing countries like India, Mexico, and Brazil. For instance, Netmeds was founded in 2015 and reached US$ 1.8 million by 2019.

"North America represents one of the largest markets of Antiepileptic Drug market"

For a better understanding of the market dynamics of the Antiepileptic Drug market, a detailed analysis was conducted for different regions across the globe including North America (U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. In 2020, North America dominated the antiepileptic drug industry. This can be mainly due to the presence of a well-established healthcare infrastructure coupled with increasing investments from private organizations and public associations for the development of effective treatment for diseases like epilepsy. Furthermore, the presence of market players and frequent product launches in the region significantly contributes to the considerable market share of the region. In June 2021, Glenmark Pharma launched the anti-epileptic drug Rufinamide in the US market.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Customization Options:

The global Antiepileptic Drug market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Antiepileptic Drug Market
• 2.2. Research Methodology of the Antiepileptic Drug Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Antiepileptic Drug Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ANTIEPILEPTIC DRUG MARKET COVID-19 IMPACT

6 GLOBAL ANTIEPILEPTIC DRUG MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY DRUG CLASS

• 7.1. First Generation
• 7.2. Second Generation
• 7.3. Third Generation

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Retail Pharmacies
• 8.2. Hospitals Pharmacies
• 8.3. Online

9 MARKET INSIGHTS BY REGION

• 9.1. North America Antiepileptic Drug Market
  • 9.1.1. United States
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe Antiepileptic Drug Market
  • 9.2.1. Germany
  • 9.2.2. France
  • 9.2.3. U.K.
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia Pacific Antiepileptic Drug Market
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Australia
  • 9.3.5. Rest of Asia Pacific
• 9.4. Rest of World Antiepileptic Drug Market

10 ANTIEPILEPTIC DRUG MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 ANTIEPILEPTIC DRUG MARKET OPPORTUNITIES

12 ANTIEPILEPTIC DRUG MARKET TRENDS

13 LEGAL & REGULATORY FRAMEWORK

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porter's Five Forces Analysis

17 COMPANY PROFILED

• 17.1. Novartis AG
• 17.2. GlaxoSmithKline Plc
• 17.3. Johnson & Johnson Service Inc
• 17.4. Teva Pharmaceutical Industries Ltd.
• 17.5. Pfizer Inc.
• 17.6. Zogenix
• 17.7. Dr. Reddy's Laboratories Ltd.
• 17.8. Alkem Labs
• 17.9. SK Biopharmaceuticals
• 17.10. Eisai Co.

18 DISCLAIMER